Maternal immunization to modulate the development of allergic response and pathogen infections

Immunotherapy

Volumn 1, Issue 1, 2009, Pages 141-156

  Rigato, Paula Ordonhez ^a   Fusaro, Ana Elisa ^a   Victor, Jefferson Russo ^a   Notomi Sato, Maria ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Allergy; Breastfeeding; DNA vaccines; Immunotherapy; Infections; Maternal antibodies; Maternal immunomodulation; Neonatal intervention; Pregnancy

Indexed keywords

ALLERGEN; ANTIGEN; BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; BCG VACCINE; CHICKENPOX VACCINE; DNA VACCINE; FOOD ALLERGEN; HEPATITIS A VACCINE; INFLUENZA VACCINE; MEASLES VACCINE; MUMPS VACCINE; POLIOMYELITIS VACCINE; RECOMBINANT PROTEIN; RUBELLA VACCINE; TETANUS TOXOID;

ADAPTIVE IMMUNITY; ALLERGIC REACTION; BACTERIAL INFECTION; BASIC RESEARCH; CHICKENPOX; CHILDHOOD DISEASE; DNA IMMUNIZATION; HEPATITIS A; HUMAN; IMMUNIZATION; IMMUNOCOMPETENCE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFECTION; INFECTION PREVENTION; INFLUENZA; INNATE IMMUNITY; MEASLES; MUMPS; NONHUMAN; POLIOMYELITIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RUBELLA; TETANUS; TUBERCULOSIS; VIRUS INFECTION;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIGEN-ANTIBODY COMPLEX; CYTOKINES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; HYPERSENSITIVITY; IMMUNITY, MATERNALLY-ACQUIRED; INFANT, NEWBORN; INFECTION; INFECTION CONTROL; PREGNANCY; RECEPTORS, FC; TH1-TH2 BALANCE; VACCINATION;

EID: 77951242948     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/1750743X.1.1.141     Document Type: Review

References (178)

1. Downs SH, Marks GB, Sporik R et al.: Continued increase in the prevalence of asthma and atopy. Arch. Dis. Child 84(1), 20-23 (2001).
2. Host A, Andrae S, Charkin S et al.: Allergy testing in children: why, who, when and how? Allergy 58(7), 559-569 (2003).
3. Warner JO: The early life origins of asthma and related allergic disorders. Arch. Dis. Child 89, 97-102 (2004).
4. Brussee JE, Smit HA, van Strien RT et al.: Allergen exposure in infancy and the development of sensitization, wheeze, and asthma at 4 years. J. Allergy Clin. Immunol. 115(5), 946-952 (2005).
5. Vonk JM, Boezen HM, Postma DS et al.: Perinatal risk factors for bronchial hyperresponsiveness and atopy after a follow-up of 20 years. J. Allergy Clin. Immunol. 114(2), 270-276 (2004).
6. Ege MJ, Herzum I, Büchele G et al.; Protection Against Allergy Study in Rural Environments (PASTURE) Study Group: Prenatal exposure to a farm environment modifies atopic sensitization at birth. J. Allergy Clin. Immunol. 122(2), 407-412 (2008).
7. Prescott SL: Maternal allergen exposure as a risk factor for childhood asthma. Curr. Allergy Asthma Rep. 6(1), 75-80 (2006).
8. Riedler J, Braun-Fahrländer C, Eder W et al.: Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet 358, 1129-1133 (2001). (Pubitemid 32971845)
9. Liu CA, Wang CL, Chuang H et al.: Prenatal prediction of infant atopy by maternal but not paternal total IgE levels. J. Allergy Clin. Immunol. 112(5), 899-904 (2003).
10. Tariq SM, Matthews S, Stevens M et al.: Epidemiology of allergic disorders in early childhood. Pediatr. Pulmonal. Suppl. 16, 69 (1997).
11. Sadeghnejad A, Karmaus W, Davis S et al.: Raised cord serum immunoglobulin E increases the risk of allergic sensitisation at ages 4 and 10 and asthma at age 10. Thorax 59(11), 936-942 (2004). (Pubitemid 39490776)
12. Yang KD, Ou CY, Hsu TY et al.: Interaction of maternal atopy, CTLA-4 gene polymorphism and gender on antenatal immunoglobulin E production. Clin. Exp. Allergy 37(5), 680-687 (2007).
13. Bottema RW, Reijmerink NE, Kerkhof M et al.: Interleukin 13, CD14, pet and tobacco smoke influence atopy in three Dutch cohorts: the allergenic study. Eur. Respir. J. 32(3), 593-602 (2008).
14. Dealtry GB, O'Farrell MK, Fernandez N: The Th2 cytokine environment of the placenta. Int. Arch. Allergy Immunol. 123, 107-119 (2000).
15. Wegmann, TG, Lin H, Guilbert L et al.: Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a Th2 phenomenon? Immunology Today 14, 343-356 (1993).
16. Chaouat G, Dubanchet S, Ledée N: Cytokines: important for implantation? J. Assist. Reprod. Genet. 24(11), 491-505 (2007).
17. Kopp MV, Zehle C, Pichler J et al.: Allergen-specific T cell reactivity in cord blood: the influence of maternal cytokine production. Clin. Exp. Allergy 31, 1536-1543 (2001).
18. Macaubas C, Klerk NH, Holt BJ et al.: Association between antenatal cytokine production and the development of atopy and asthma at age 6 years. Lancet 362, 1192-1197 (2003). (Pubitemid 37255345)
19. Tang ML, Kemp AS, Thorburn J et al.: Reduced interferon-γ secretion in neonates and subsequent atopy. Lancet 344, 983-985 (1994). (Pubitemid 2140437)
20. Uthoff H, Spenner A, Reckelmamm W et al.: Critical role of preconceptional immunization for protective and nonpathological specifc immunity im murine neonates. J. Immunol. 171, 3485-3492 (2003). (Pubitemid 37254550)
21. Spencer J, MacDonald TT, Finn T et al.: The development of gut associated lymphoid tissue in the terminal ileum of fetal human intestine. Clin. Exp. Immunol. 13 (64), 536-543 (1986).
22. Holloway JA, Warner JO, Vance GHS et al.: Detection of house-dust-mite allergen in amniotic fluid and umbilical-cord blood. Lancet, 356, 1900-1902 (2000).
23. Thornton CA, Vance GHS: The placenta: a portal of fetal allergen exposure. Clin. Exp. Allergy. 32, 1537-1539 (2002).
24. Szépfalusi Z, Loibichler C, Pichler J et al.: Direct evidence for transplacental allergen transfer. Pediatr. Res. 48, 404-407 (2000).
25. Edelbauer M, Loibichler C, Nentwich I et al.: Maternally delivered nutritive allergens in cord blood and in placental tissue of term and preterm neonates. Clin. Exp. Allergy 34, 189-193 (2004).
26. Szépfalusi Z, Loibichler C, Pichler J et al.: Most of diaplacentally transferred allergen is retained in the placenta. Clin. Exp. Allergy 36, 1130-1137 (2006).
27. Prescott SH, Macaubas C, Holt PG et al.: Transplacental priming of the human immune system to environmental allergens: Universal skewing of initial T cell responses toward the Th2 cytokine profile. J. Immunology. 160, 4730-4737 (1998). (Pubitemid 28215305)
28. Jones CA, Kilburn SA, Warner JA et al.: Intrauterine environment and fetal allergic sensitization. Clin. Exp. Allergy 28, 655-659 (1998).
29. + T regulatory cells in human neonatal T cell responses to environmental antigens/allergens. J. Immunol. 173, 3084-3092 (2004).
30. Piccinni MP, Mecacci F, Sampognaro S et al.: Aeroallergen sensitization can occur during fetal life. Int. Arch. Allergy Immunol. 102, 301-303 (1993).
31. Jones CA, Miles EA, Warner JO et al.: Fetal peripheral blood mononuclear cell proliferation responses to mitogenic and allergenic stimuli during gestation. Pediatr. Allergy Immunol. 7, 109-116 (1996).
32. Chan-Yeung M, Ferguson A, Chan H et al.: Umbilical cord blood mononuclear cell proliferative response to house dust mite does not predict the development of allergic rhinits and asthma. J. Allergy Clin. Immunol. 104, 317-321 (1999).
33. Platts-Mills T: Cord blood proliferative responses to inhaled allergens: is there a phenomenon? J. Allergy Clin. Immunol. 106, 441-443 (2000).
34. Smillie FI, Elderfield AJ, Patel F et al.: Lymphoproliferative response in cord blood and at one year: no evidence for effect of in utero exposure to dust mite allergens. Clin. Exp. Allergy 31, 1194-1204 (2001).
35. Bønnelykke K, Pipper CB, Bisgaard H: Sensitization does not develop in utero. J. Allergy Clin. Immunol. 121, 646-651 (2008).
36. Kihlstrom A, Lilja G, Pershagen G et al.: Exposure to high doses of birch pollen during pregnancy, and risk of sensitization and atopic disease in the child. Allergy 58, 871-877 (2003). (Pubitemid 37046685)
37. Kihlström A, Lilja G, Pershagen G et al.: Maternal pollen allergy may be more important than birch pollen exposure during pregnancy for atopic airway disease in the child. Pediatr. Allergy Immunol. 15, 497-505 (2004).
38. Rowe J, Kusel M, Holt BJ et al.: Prenatal versus postnatal sensitization to environmental allergens in a high-risk birth cohort. J. Allergy Clin. Immunol. 119(5), 1164-1173 (2007).
39. Van de Perre P: Transfer of antibody via mother's milk. Vaccine 21, 3374-3376 (2003).
40. Keeney SE, Schmalstieg FC, Palkowetz KH et al.: Activated neutrophils and neutrophil activators in human milk: increased expression of CD11b and decreased expression of L-selectin. J. Leuko. Biol. 54, 97-104 (1993).
41. Saarinen UM, Kajosaari M, Blackman A et al.: Prolonged breast-feeding as prophylaxis for atopic disease. Lancet 2(8135), 163-166 (1979). (Pubitemid 10232449)
42. Kull I, Almqvist C, Lilja G et al.: Breast-feeding reduces the risk of asthma during the first 4 years of life. J. Allergy Clin. Immunol. 114(4), 755-1600 (2004).
43. Saarinen UM, Kajosaari M: Breastfeeding as prophylaxis againts atopic disease: prospective follow-up study until 17 years old. Lancet 346, 1065-1069 (1995).
44. Oddy WH, Holt PG, Sly PD et al.: Association between breast-feeding and asthma in 6 year old children: findings of a prospective birth cohort study. Br. Med. J. 319(7213), 815-819 (1999).
45. Chulada PC, Arbes SJ Jr, Dunson D et al.: Breast-feeding and the prevalence of asthma and wheeze in children: analyses from the Third National Health and Nutrition Examination Survey, 1988-1994. J. Allergy Clin. Immunol. 111(2), 328-336 (2003).
46. Kull I, Wickman M, Lilja G et al.: Breast feeding and allergic diseases in infants - a prospective birth cohort study. Arch. Dis. Child. 87(6), 478-481 (2002).
47. Kramer MS, Matush L, Vanilovich I et al.; Promotion of Breastfeeding Intervention Trial (PROBIT) Study Group: Effect of prolonged and exclusive breast feeding on risk of allergy and asthma: cluster randomised trial. Br. Med. J. 335(7624), 815 (2007).
48. Bottcher M, Lain F, Jenmalm M et al.: Cytokines in breast milk from allergic and nonallergic mothers. Pediatr. Res. 47(1), 157-162 (2000).
49. Cant A, Mardsen RA, Kilshaw PJ: Egg and cows' milk hypersensitivity in exclusively breast fed infants with eczema and detection of egg protein in breast milk. Br. Med. J. 291(6500), 932-935 (1985).
50. Troncone R, Scarcella A, Donatiello A et al.: Passage of gliadin into human breast milk. Acta Pediatric. Scand. 76(3), 453-456 (1987).
51. Vance GHS, Lewis SA, Grimshaw KEC et al.: Exposure of the fetus and infant to hens' egg ovalbumin via the placent and breast milk in relation to maternal intake of dietary egg. Clin. Exp. Allergy 35 (10), 1318-1326 (2005).
52. Hattevig G, Kjellman B, Sigurs N et al.: Effect of maternal avoidance of eggs, cow's milk and fish during lactation upon allergic manifestations in infants. Clin. Exp. Allergy 19(1), 27-32 (1989).
53. Chandra RK, Puri S, Hamed A: Influence of maternal diet during lactation and use of formula feeds on development of atopic eczema in high risk infants. Br. Med. J. 299(6693), 228-230 (1989).
54. Businco L, Marchetti F, Pellegrini G et al.: Prevention of atopic disease in 'at-risk newborns' by prolonged breast-feeding. Ann. Allergy 51(2 Pt 2), 296-299 (1983).
55. Chandra RK, Puri S, Suraiya C et al.: Influence of maternal food antigen avoidance during pregnancy and lactation on incidence of atopic eczema in infants. Clin. Allergy 16(6), 563-569 (1986). (Pubitemid 17181883)
56. Oddy WH, Peat JK, de Klerk NH: Maternal asthma, infant feeding, and the risk of asthma in childhood. J. Allergy Clin. Immunol. 110(1), 65-67 (2002).
57. Fergusson DM, Horwood LJ: Early solid food diet and eczema in childhood: a 10-year longitudinal study. Pediatr. Allergy Immunol. 5(Suppl. 6), 44-47 (1994).
58. Arshad SH, Kurukulaaratchy RJ, Fenn M et al.: Early life risk factors for current wheeze, asthma, and bronchial hyperresponsiveness at 10 years of age. Chest 127(2), 502-508 (2005). (Pubitemid 40229309)
59. Alm JS, Lilja G, Pershagen G et al.: Early BCG vaccination and development of atopy. Lancet 350(9075), 400-403 (1997). (Pubitemid 27331234)
60. Herrmann ME, Dannemann A, Grüters A et al.: Prospective study of the atopy preventive effect of maternal avoidance of milk and eggs during pregnancy and lactation. Eur. J. Pediatr. 155(9), 770-774 (1996).
61. Devereux G, Seaton A: Diet as a risk factor for atopy and asthma. J. Allergy Clin. Immunol. 115(6), 1109-1117 (2005).
62. Penders J, Stobberingh EE, van den Brandt PA, Thijs C: The role of the intestinal microbiota in the development of atopic disorders. Allergy 62(11), 1223-1236 (2007). (Pubitemid 47537504)
63. Kalliomäki M, Salminen S, Arvilommi H et al.: Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 357(9262), 1076-1079 (2001). (Pubitemid 32322538)
64. Kukkonen K, Savilahti E, Haahtela T et al.: Probiotics and prebiotic galactooligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 119(1), 192-198 (2007).
65. Huurre A, Laitinen K, Rautava S et al.: Impact of maternal atopy and probiotic supplementation during pregnancy on infant sensitization: a double-blind placebo-controlled study. Clin. Exp. Allergy 38(8), 1342-1348 (2008).
66. Kopp MV, Hennemuth I, Heinzmann A et al.: Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics 121(4), 850-856 (2008).
67. Carter AM: Sources for comparative studies of placentation I. Embryological collections. Placenta 29(1), 95-98 (2008).
68. Moffett A, Loke C: Implantation, embryo-maternal interactions, immunology and modulation of the uterine environment - a workshop report. Placenta 27 (Suppl A), S54-S55 (2006).
69. Roberts SA, Turner MW: Specific suppression of rat IgE responses with milk from immunized females and with feeds of serum antibody. Immunology 8(1), 195-199 (1983).
70. Jarret EEE, Hall E: Selective supression of IgE antibody responsiveness by maternal influence. Nature 280, 145-147 (1979). ■■ Report on suppression of the IgE response in offspring by maternal factors transferred through breastfeeding.
71. Jarret EEE, Hall E: IgE suppression by maternal IgG. Immunology 48, 49-58 (1983).
72. Jarret EEE, Hall E: The development of IgE-suppressive imuno-competence in young animals: influence of exposure to antigen in the presence or absence of maternal immunity. Immunology 53, 365-373 (1984).
73. Jarrett EEE: Perinatal influences on IgE responses. Lancet 2(8406), 797-799 (1984).
74. Telemo E, Jakobsson I, Weström BR et al.: Maternal dietary antigens and the immune response in the offspring of the guinea-pig. Immunology 62(1), 35-38 (1987). (Pubitemid 17141374)
75. Melkild I, Groeng EC, Leikvold RB et al.: Maternal allergen immunization during pregnancy in a mouse model reduces adult allergy-related antibody responses in the offspring. Clin. Exp. Allergy 32, 1370-1376 (2002).
76. Fusaro AE, Maciel M, Victor JR et al.: Influence of maternal murine immunization with Dermatophagoides pteronyssinus extract on the type I hypersensitivity response in offspring. Int. Arch. Allergy Immunol. 127(3), 208-216 (2002).
77. Fusaro AE, Brito CA, Victor JR et al.: Maternal-fetal interaction: preconception immunization in mice prevents neonatal sensitization induced by allergen exposure during pregnancy and breastfeeding. Immunology 122(1), 107-115 (2007).
78. Victor JR, Fusaro AE, Duarte AJS et al.: Preconceptional maternal immunization to dust mite inhibits the type I hypersensitivity response of offspring. J. Allergy Clin. Immunol. 111(2), 269-277 (2003).
79. Siegrist CA: Neonatal and early life vaccinology. Vaccine 19(25-26), 3331-3346 (2001). ■■ Reviewed preclinical and human vaccine studies and indicated that neonatal immunization may result in efficient immunological priming for future immune responses.
80. Jerne NK: Idiotypic networks and other preconceived ideas. Immunol. Rev. 79, 5-24 (1984). ■■ Characterization of the idiotypic network.
81. Seeger M, Thierse HJ, Lange H et al.: Antigen-independent suppression of the IgE immune response to bee venom phospholipase A2 by maternally derived monoclonal IgG antibodies. Eur. J. Immunol. 28(7), 2124-2130 (1989).
82. Hiernaux J, Bona C, Baker PJ: Neonatal treatment with low doses of anti-idiotypic antibody leads to the expression of a silent clone. J. Exp. Med. 153(4), 1004-1008 (1981).
83. Borghesi C, Nicoletti C: Autologous anti-idiotypic antibody response is regulated by the level of circulating complementary idiotype. Immunology 89(2), 172-177 (1996). (Pubitemid 26340118)
84. Vakil M, Sauter H, Paige C et al.: In vivo suppression of perinatal multispecific B cells results in a distortion of the adult B cell repertoire. Eur. J. Immunol. 16(9), 1159-1165 (1986).
85. Bogen B, Dembic Z, Weiss S: Clonal deletion of specific thymocytes by an immunoglobulin idiotype. EMBO J. 12(1), 357-363 (1993). (Pubitemid 23042415)
86. Amigorena S, Salamero J, Davoust J et al.: Tyrosine-containing motif that transduces cell activation signals also determines internalization and antigen presentation via type III receptors for IgG. Nature 358(6384), 337-341 (1992).
87. Muta T, Kurosaki T, Misulovin Z et al.: A 13-amino-acid motif in the cytoplasmic domain of Fc γ RIIB modulates B-cell receptor signalling. Nature 369(6478), 340 (1994).
88. Heyman B: Functions of antibodies in the regulation of B cell responses in vivo. Springer Semin. Immunopathol. 23(4), 421-432 (2001).
89. Karlsson MC, Wernersson S, Diaz de Ståhl T et al.: Efficient IgG-mediated suppression of primary antibody responses in Fcγ receptor-deficient mice. Proc. Natl Acad. Sci. USA 96(5), 2244-2249 (1999).
90. Sohn HW, Tolar P, Pierce SK: Membrane heterogeneities in the formation of B cell receptor-Lyn kinase microclusters and the immune synapse. J. Cell. Biol. 182(2), 367-379 (2008). «■ New pathway on the control of B-cell receptor activation.
91. Wernersson S, Karlsson MC, Dahlström J et al.: IgG-mediated enhancement of antibody responses is low in Fc receptor γ chain-deficient mice and increased in Fc γ RII-deficient mice. J. Immunol. 163(2), 618-622 (1999). (Pubitemid 29328064)
92. Powell LD, Jain RK, Matta KL et al.; Characterization of sialyloligosaccharide binding by recombinant soluble and native cell-associated CD22. Evidence for a minimal structural recognition motif and the potential importance of multisite binding. J. Biol. Chem. 270(13), 7523-7532 (2005).
93. Kelm S, Pelz A, Schauer R et al.: Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the Immunoglobulin superfamily. Curr. Biol. 4(11), 965-972 (1994).
94. Katz HR: Inhibitory receptors and allergy. Curr. Opin. Immunol. 14(6), 698-704 (2002).
95. Nitschke L, Tsubata T: Molecular interactions regulate BCR signal inhibition by CD22 and CD72. Trends Immunol. 25(10), 543-550 (2004). (Pubitemid 39208353)
96. Ostojic S, Dubanchet S, Chaouat G et al.: Demonstration of the presence of IL-16, IL-17 and IL-18 at the murine fetomaternal interface during murine pregnancy. Am. J. Reprod. Immunol. 49(2), 101-112 (2003).
97. Matson AP, Zhu L, Lingenheld EG et al.: Maternal transmission of resistance to development of allergic airway disease. J. Immunol. 179(2), 1282-1291 (2007).
98. Lima C, Souza VM, Faquim-Mauro EL et al.: Modulation of the induction of lung and airway allergy in the offspring of IFN-γ-treated mother mice. J. Immunol. 175(6), 3554-3559 (2005). (Pubitemid 41292013)
99. Blümer N, Herz U, Wegmann M et al.: Prenatal lipopolysaccharide- exposure prevents allergic sensitization and airway inflammation, but not airway responsiveness in a murine model of experimental asthma. Clin. Exp. Allergy 35(3), 397-402 (2005).
100. Verhasselt V, Milcent V, Cazareth J et al.: Breast milk-mediated transfer of an antigen induces tolerance and protection from allergic asthma. Nat. Med. 14(2), 170-175 (2008). ■■ Transfer of an antigen from the mother to the newborn via milk induces oral tolerance and antigen-specific protection from allergic airway disease.
101. Hubeau C, Apostolou I, Kobzik L: Targeting of CD25 and glucocorticoid-induced TNF receptor family-related gene-expressing T cells differentially modulates asthma risk in offspring of asthmatic and normal mother mice. J. Immunol. 178(3), 1477-1487 (2007). (Pubitemid 46154619)
102. Schaub B, Liu J, Höppler S et al.; Impairment of T-regulatory cells in cord blood of atopic mothers. J. Allergy Clin. Immunol. 121(6), 1491-1499, (2008).
103. Johnson DC, McFarland EJ, Muresan P et al.: Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women. J. Infect. Dis. 192(12), 2129-2133 (2005).
104. Healy CM, Baker CJ: Prospects for prevention of childhood infections by maternal immunization. Curr. Opin. Infect. Dis. 19(3), 271-276 (2006).
105. Luzuriaga K, Newell ML, Dabis F et al.: Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities. Lancet 368(9534), 511-521 (2005). (Pubitemid 44142773)
106. Healy CM, Baker CJ: Maternal immunization. Pediatr. Infect. Dis J. 26(10), 945-948 (2007).
107. Siegrist CA. The challenges of vaccine responses in early life: selected examples. J. Comp. Pathol. 137(Suppl. 1), S4-S9 (2007).
108. Baril L, Briles DE, Crozier P et al.: Characterization of antibodies to PspA and PsaA in adults over 50 years of age with invasive pneumococcal disease. Vaccine 23(6), 789-793 (2001). (Pubitemid 39473177)
109. Leuridan E, Van Damme P: Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine 25(34), 6296-6304 (2007). (Pubitemid 47090234)
110. Saffar Mj, Khalilian AR, Ajami A et al.: Seroimmunity to diphtheria and tetanus among mother-infant pairs; the role of maternal immunity on infant immune response to diphtheria-tetanus vaccination. Swiss Med. Wkly 138(17-18), 256-260 (2008). (Pubitemid 351678364)
111. Watson JC, Peter G: General immunization practices. In: Vaccines. Plotkin SA, Orenstein WA (Eds). WB Saunders, PA, USA, 43-73 (1999).
112. Bricks LF: Vaccines in pregnancy: a review of their importance in Brazil. Rev. Hosp. Clin. Fac. Med. Sao Paulo 58(5), 263-274 (2003).
113. Adkins B, Leclerc C, Marshall-Clarke S: Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 4(7), 553-564 (2004).
114. Kruschinski C, Zidan M, Debertin AS et al.: Age-dependent development of the splenic marginal zone in human infants is associated with different causes of death. Hum. Pathol. 35(1), 113-121 (2004).
115. Pihlgren M, Schallert N, Tougne C et al.: Delayed and deficient establishment of the long-term bone marrow plasma cell pool during early life. Eur. J. Immunol. 31(3), 939-946 (2001).
116. Belnoue E, Pihlgren M, McGaha TL et al.: APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 111(5), 2755-2764 (2008).
117. Munoz FM, Englund JA: Vaccines in pregnancy. Infect. Dis. Clin. North Am. 15, 253-271 (2001).
118. Englund JA: The influence of maternal immunization on infant immune responses. J. Comp. Pathol. 137(1), 16-19 (2007).
119. Sato H, Albrecht P, Reynolds DW et al.: Transfer of measles, mumps, and rubella antibodies from mother to infant. Its effect on measles, mumps, and rubella immunization. Am. J Dis. Child. 133(12), 1240-1243 (1979). (Pubitemid 10205400)
120. Saji F, Samejima Y, Kamiura S et al.: Dynamics of immunoglobulins at the feto-maternal interface. Rev. Reprod. 4(2), 81-89 (1999).
121. Glezen WP: Effect of maternal antibodies on the infant immune response. Vaccine 28, 21(24), 389-392 (2003).
122. Roper MH, Vandelaer JH, Gasse FL: Maternal and neonatal tetanus. Lancet 370(9603), 1947-1959 (2007).
123. Albrecht P, Ennis FA, Saltzman EJ et al.: Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J. Pediatr. 91(5), 715-718 (1977). ■ Demonstrates a probable mechanism for measles vaccine failure in 12-month-old children and suggests postponing measles vaccination to 15 months of age. (Pubitemid 8207589)
124. Stetler HC, Orenstein WA, Bernier RH et al.: Impact of revaccinating children who initially received measles vaccine before 10 months of age. Pediatrics 77(4), 471-476 (1986).
125. Johnson CE, Nalin DR, Chui LW et al.: Measles vaccine immunogenicity in 6- versus 15-month-old infants born to mothers in the measles vaccine era. Pediatrics 93(6 Pt 1), 939-944 (1994).
126. Gans HA, Maldonado Y, Yasukawa LL et al.: IL-12, IFN-γ, and T cell proliferation to measles in immunized infants. J. Immunol. 162(9), 5569-5575 (1999).
127. Perkins FT, Yetts R, Gaisford W: A comparison of the responses of 100 infants to primary poliomyelitis immunization with two and with three doses of vaccine. Br. Med. J. 1(5129), 1083-1086 (1959). ■■ Demonstrates that the response of infants to poliomyelitis vaccine is governed by the level of maternal antibody and the number of antigenic stimuli given in primary immunization.
128. Burstyn DG, Baraff LJ, Peppier MS et al.: Serological response to filamentous hemagglutinin and lymphocytosis-promoting toxin of Bordetella pertussis. Infect. Immun. 41(3), 1150-1156 (1983).
129. Englund JA, Anderson EL, Reed GF et al.: The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 96 (3 Pt 2), 580-584 (1995).
130. Barr M, Glenny AT, Randall KJ: Diphtheria Immunization in young babies; a study of some factors involved. Lancet 1 (6593), 6-10 (1995).
131. Sarvas H, Kurikka S, Seppälä IJ et al.: Maternal antibodies partly inhibit an active antibody response to routine tetanus toxoid immunization in infants. J. Infect. Dis. 165(5), 977-979 (1992).
132. Bjôrkholm B, Granström M, Taranger J et al.: Influence of high titers of maternal antibody on the serologic response of infants to diphtheria vaccination at three, five and twelve months of age. Pediatr. Infect. Dis. J. 14(10), 846-850 (1995).
133. Kanra G, Yalçin SS, Ceyhan M et al.: Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children. Turk. J. Pediatr. 42(2), 105-108 (2000).
134. Siegrist CA: Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 21(24), 3406-3412 (2003). ■■ Focused on several mechanisms that have been suggested as mediating the inhibitory influence of maternal antibodies on infant responses.
135. Boyle CM, Robinson HL: Basic mechanisms of DNA-raised antibody responses to intramuscular and gene gun immunizations. DNA Cell. Biol. 19(3), 157-165 (2000).
136. PertmerTM, Oran AE, Moser JM et al.: DNA vaccines for influenza virus: differential effects of maternal antibody on immune responses to hemagglutinin and nucleoprotein. J. Virol. 74(17), 7787-7793 (2000).
137. Manickan E, Yu Z, Rouse BT: DNA immunization of neonates induces immunity despite the presence of maternal antibody. J. Clin. Invest. 100(9), 2371-2375 (1997).
138. Premenko-Lanier M, Rota PA, Rhodes GH et al.: Protection against challenge with measles virus (MV) in infant macaques by an MV DNA vaccine administered in the presence of neutralizing antibody. J. Infect. Dis. 89(11), 2064-2071 (2003).
139. Siegrist CA, Barrios C, Martinez X et al.: Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. Eur. J. Immunol. 28(12), 4138-4148 (1998). ■■ Effective vaccine responses could be obtained earlier in the presence of maternal antibodies using appropriate immunization strategies with conventional or DNA vaccines.
140. Kirby DJ, Rosenkrands I, Agger EM et al.: PLGA microspheres for the delivery of a novel subunit TB vaccine. J. Drug Target 16(4), 282-293 (2008). (Pubitemid 351622358)
141. Davis SS: The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery. Vaccine 24(Suppl. 2), S2(7-10) (2006).
142. Hägglund S, Hu KF, Larsen LE et al.: Bovine respiratory syncytial virus ISCOMs - protection in the presence of maternal antibodies. Vaccine 23 (5), 646-655 (2004). (Pubitemid 39473194)
143. Pahine A, Valiante NM, Ulmer JB: Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11(Suppl. 4), S63-S68 (2004).
144. Hassett DE, Zhang J, Whitton JL: Neonatal DNA immunization with a plasmid encoding an internal viral protein is effective in the presence of maternal antibodies and protects against subsequent viral challenge. J. Virol. 71(10), 7881-7888 (1997). (Pubitemid 27391738)
145. Zhang F, Chen J, Fang F et al.: Maternal immunization with both hemagglutinin- and neuraminidase-expressing DNAs provides an enhanced protection against a lethal influenza virus challenge in infant and adult mice. DNA Cell. Biol. 24(11), 758-765 (2005).
146. Chen J, Zhang F, Fang F et al.: Vaccination with hemagglutinin or neuraminidase DNA protects BALB/c mice against influenza virus infection in presence of maternal antibody. BMC Infect. Dis. 16, 7-118 (2007).
147. Marshall-Clarke S, Reen D, Tasker L et al.: Neonatal immunity: how well has it grown up? Immunol. Today 21(1), 35-41 (2000). (Pubitemid 30410697)
148. Boyer JD, Chattergoon MA, Ugen KE et al.: Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial. Clin. Immunol. 90(1), 100-107 (1999).
149. Mulligan MJ, Russell ND, Celum C et al.: Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adult. AIDS Res. Hum. Retroviruses 22(7), 678-683 (2006).
150. Marques ET Jr, Chikhlikar P, de Arruda LB et al.: HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses. J. Biol. Chem. 278(39), 37926-37936 (2003).
151. Chikhlikar P, de Arruda LB, Maciel M et al.: DNA encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in Rhesus macaques. PLoS ONE 27(1). E135 (2006).
152. McFarland EJ, Borkowsky W, Fenton T et al.: Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J. Infect. Dis. 184(10), 1331-1335. (2001).
153. Borkowsky W, Wara D, Fenton T et al.: Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. J. Infect. Dis. 181(3), 890-896 (2000).
154. Flynn NM, Forthal DN, Harro CD et al.: The rgp120 HIV Vaccine Study Group. Placebo-controlled Phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191(5), 154-165 (2005).
155. Pitisuttihum P: HIV-1 prophylactic vaccine trials in Thailand. Curr. HIV Res. 3(1), 17-30 (2005).
156. McFarland EJ, Johnson DC, Muresan P et al.: HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS 20(11), 1481-1489 (2002). (Pubitemid 44100208)
157. Xu W, Hofmann-Lehmann R, McClure HM et al.: Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV. Vaccine 20(15), 1956-1960 (2002).
158. Safrit JT, Ruprecht R, Ferrantelli F et al.: Ghent IAS Working Group on HIV in Women Children. Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. J. Acquir. Immune Defic. Syndr. 35(2), 169-177 (2004).
159. Sedegah M, Belmonte M, Epstein JE et al.: Successful induction of CD8 T cell-dependent protection against malaria by sequential immunization with DNA and recombinant poxvirus of neonatal mice born to immune mothers. J. Immunol. 171(6), 3148-3153 (2003). (Pubitemid 37093539)
160. Brave A, Johansen K, Palma P et al.: Maternal immune status influences HIV-specific immune responses in pups after DNA prime protein boost using mucosal adjuvant. Vaccine 16 (2008).
161. Sasaki S, Kojima Y et al.: Detection of progeny immune responses after intravenous administration of DNA vaccine to pregnant mice. Biol. Proced. Online 3, 91-101 (2002).
162. Okuda K, Xin KQ, Haruki A et al.: Transplacental genetic immunization after intravenous delivery of plasmid DNA to pregnant mice. J. Immunol. 167(9), 5478-5484 (2001). (Pubitemid 33009790)
163. Rizzi M, Gerloni M, Srivastava AS et al.: In utero DNA immunisation. Immunity over tolerance in fetal life. Vaccine 23(33), 4273-4282 (2005).
164. Gerdts V, Babiuk LA, van Drunen Littel-van den Hurk et al.: Fetal immunization by a DNA vaccine delivered into the oral cavity. Nat. Med. 6(8), 929-932 (2000).
165. Gerdts V, Snider M, Brownlie R et al.: Oral DNA vaccination in utero induces mucosal immunity and immune memory in the neonate. J. Immunol. 168(4), 1877-1885 (2002).
166. Tsang CH, Mirakhur KK, Babiuk LA et al.: Oral DNA immunization in the second trimester fetal lamb and secondary immune responses in the neonate. Vaccine 25(50), 8469-8479 (2007).
167. Tan LK, Huang CH, Kuo IC et al.: Intramuscular immunization with DNA construct containing Der p 2 and signal peptide sequences primed strong IgE production. Vaccine 24(29-30), 5762-5771 (2006).
168. Hartl A, Hochreiter R, Stepanoska T et al.: Characterization of the protective and therapeutic efficiency of a DNA vaccine encoding the major birch pollen allergen Bet ν 1a. Allergy 59(1), 65-73 (2004). (Pubitemid 38167954)
169. Hochreiter R, Stepanoska T, Ferreira F et al.: Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet ν 1, the major birch-pollen allergen. Eur J. Immunol. 33(6), 1667-1676 (2003).
170. Kwon SS, Kim N, Yoo TJ: The effect of vaccination with DNA encoding murine T-cell epitopes on the Der p 1 and 2 induced immunoglobulin E synthesis. Allergy 56(8), 741-748 (2001).
171. Arruda LB, Chikhlikar PR, August JT et al.: DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response. Immunology 112(1), 126-133 (2004).
172. Jin H, Kang Y, Zhao L et al.: Induction of adaptive T regulatory cells that suppress the allergic response by coimmunization of DNA and protein vaccines. J. Immunol. 180(8), 5360-5372 (2008).
173. World Health Organization. What are the key health dangers for children? www.who.int/features/qa/13/en/index.html
174. World Health Organization. The world health report 2007 - A safer future: global public health security in the 21st Century. www.who.int/whr/2007/en/ index.html
175. Centers for Disease Control and Prevention. www.cdc.gov/vaccines/pubs/ preg-guide.html
176. Centers for Disease Control and Prevention. Vaccines and immunizations. www.cdc.gov/vaccines
177. Joint United Nations Programme on HIV/AIDS. www.unaids.org
178. Unite for Children. www.unicef.org/health/index-malaria.html